treatment resistant heroin addiction
Conditions
Interventions
Trade Name: Diacetylmorfine, poeder voor inhalatiedamp (75 mg, 100 mg, 150 mg and 200 mg)
Product Name: Diacetylmorphine
Product Code: Diacetylmorphine
Pharmaceutical Form: Inhalation powder
INN or Pr
Sponsors
University of Liège
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Treatment-resistant heroin dependency, as indicated by: - heroin dependency for at least 5 years, - heroin addiction is the main dependency, - daily or almost daily use of illicit heroin, - previous experience of methadone treatment, Legal resident in the judicial district of Liège for at least 12 months, A minimum age of 20 years, Willing to attend the treatment site at least twice a day, Willing to attend a psychosocial follow-up Written consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Persons who had voluntary phase of abstinence of at least 2 months during the last 12 months Pregnancy Diagnosis of severe medical or psychiatric conditions that are contra-indicated for the study conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Comparison of the efficacy of a heroin-assisted treatment versus existing treatments;Secondary Objective: Comparison of the feasibility and cost-effectiveness of diacetylmorphine assisted treatment versus existing treatments;Primary end point(s): The better efficacy will be shown by a higher number of responders in a group. A responder is a patient who shows after 12 months a better health (physical or mental) and/or a decrease in street heroin use and/or a decrease in criminal behaviour. | — |
Countries
Belgium
Outcome results
None listed